Cautious use of intrathecal baclofen in walking spastic patients: Results on long-term follow-up

Research output: Contribution to journalArticle

Abstract

Intrathecal baclofen is presently the most effective treatment for diffuse spasticity whatever the cause. The fact that both spasticity is always accompanied by a degree of muscle weakness and that any antispastic treatment causes a decrease in muscle strength indicate that major attention must be paid in treating spasticity in ambulant patients. Methods. We present here a retrospective study, approved by the insitutional ethics committee, of 22 ambulant spastic patients, selected as homogeneous for disease and disease duration, who were treated with intrathecal baclofen at the Istituto Nazionale Neurologico "C.Besta" in Milan. These patients were followed-up for to 15 years of treatment and their clinical assessment was enriched by the evaluation of their functional independence measurement (FIM) before and during treatment. Results. There was improvement in quality of life as measured by the FIM scale; however, an increase in the patient's motor performance could not be detected. Conclusion. Although we did not show any improvement in muscle performance, intrathecal baclofen did improve daily quality of life, even in spastic patients who were able to walk.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalNeuromodulation
Volume9
Issue number2
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Baclofen
Muscle Spasticity
Walking
Quality of Life
Ethics Committees
Muscle Weakness
Muscle Strength
Therapeutics
Retrospective Studies
Muscles

Keywords

  • FIM
  • Intrathecal baclofen
  • Spasticity

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neuroscience(all)

Cite this

Cautious use of intrathecal baclofen in walking spastic patients : Results on long-term follow-up. / Dones, Ivano; Nazzi, Vittoria; Tringali, Giovanni; Broggi, Giovanni.

In: Neuromodulation, Vol. 9, No. 2, 04.2006, p. 87-93.

Research output: Contribution to journalArticle

@article{656c0e0de0064a4e87131dcf75cca6b6,
title = "Cautious use of intrathecal baclofen in walking spastic patients: Results on long-term follow-up",
abstract = "Intrathecal baclofen is presently the most effective treatment for diffuse spasticity whatever the cause. The fact that both spasticity is always accompanied by a degree of muscle weakness and that any antispastic treatment causes a decrease in muscle strength indicate that major attention must be paid in treating spasticity in ambulant patients. Methods. We present here a retrospective study, approved by the insitutional ethics committee, of 22 ambulant spastic patients, selected as homogeneous for disease and disease duration, who were treated with intrathecal baclofen at the Istituto Nazionale Neurologico {"}C.Besta{"} in Milan. These patients were followed-up for to 15 years of treatment and their clinical assessment was enriched by the evaluation of their functional independence measurement (FIM) before and during treatment. Results. There was improvement in quality of life as measured by the FIM scale; however, an increase in the patient's motor performance could not be detected. Conclusion. Although we did not show any improvement in muscle performance, intrathecal baclofen did improve daily quality of life, even in spastic patients who were able to walk.",
keywords = "FIM, Intrathecal baclofen, Spasticity",
author = "Ivano Dones and Vittoria Nazzi and Giovanni Tringali and Giovanni Broggi",
year = "2006",
month = "4",
doi = "10.1111/j.1525-1403.2006.00052.x",
language = "English",
volume = "9",
pages = "87--93",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Cautious use of intrathecal baclofen in walking spastic patients

T2 - Results on long-term follow-up

AU - Dones, Ivano

AU - Nazzi, Vittoria

AU - Tringali, Giovanni

AU - Broggi, Giovanni

PY - 2006/4

Y1 - 2006/4

N2 - Intrathecal baclofen is presently the most effective treatment for diffuse spasticity whatever the cause. The fact that both spasticity is always accompanied by a degree of muscle weakness and that any antispastic treatment causes a decrease in muscle strength indicate that major attention must be paid in treating spasticity in ambulant patients. Methods. We present here a retrospective study, approved by the insitutional ethics committee, of 22 ambulant spastic patients, selected as homogeneous for disease and disease duration, who were treated with intrathecal baclofen at the Istituto Nazionale Neurologico "C.Besta" in Milan. These patients were followed-up for to 15 years of treatment and their clinical assessment was enriched by the evaluation of their functional independence measurement (FIM) before and during treatment. Results. There was improvement in quality of life as measured by the FIM scale; however, an increase in the patient's motor performance could not be detected. Conclusion. Although we did not show any improvement in muscle performance, intrathecal baclofen did improve daily quality of life, even in spastic patients who were able to walk.

AB - Intrathecal baclofen is presently the most effective treatment for diffuse spasticity whatever the cause. The fact that both spasticity is always accompanied by a degree of muscle weakness and that any antispastic treatment causes a decrease in muscle strength indicate that major attention must be paid in treating spasticity in ambulant patients. Methods. We present here a retrospective study, approved by the insitutional ethics committee, of 22 ambulant spastic patients, selected as homogeneous for disease and disease duration, who were treated with intrathecal baclofen at the Istituto Nazionale Neurologico "C.Besta" in Milan. These patients were followed-up for to 15 years of treatment and their clinical assessment was enriched by the evaluation of their functional independence measurement (FIM) before and during treatment. Results. There was improvement in quality of life as measured by the FIM scale; however, an increase in the patient's motor performance could not be detected. Conclusion. Although we did not show any improvement in muscle performance, intrathecal baclofen did improve daily quality of life, even in spastic patients who were able to walk.

KW - FIM

KW - Intrathecal baclofen

KW - Spasticity

UR - http://www.scopus.com/inward/record.url?scp=33645762505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645762505&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1403.2006.00052.x

DO - 10.1111/j.1525-1403.2006.00052.x

M3 - Article

C2 - 22151631

AN - SCOPUS:33645762505

VL - 9

SP - 87

EP - 93

JO - Neuromodulation

JF - Neuromodulation

SN - 1094-7159

IS - 2

ER -